→
Investors may want to consider the mix of high EPS growth alongside modest revenue growth when evaluating Gilead Sciences, Inc.
Gilead Sciences, Inc. has a market capitalization of $182.90B and a current price of $145.74, reflecting a decrease of 0.62% from the previous close of $146.64. The company has a P/E ratio of 21.49 and a revenue growth of 2.40% year-over-year, while its EPS growth shows a significant increase of 1684.21%. The stock's 52-week high and low are $157.27 and $109, respectively.
Some investors highlight Gilead's impressive EPS growth of 1684.21% as a sign of potential profitability improvement. Additionally, the company’s strong return on equity (ROE) of 37.48% suggests effective management and capital utilization.
Conversely, Gilead's revenue growth of only 2.40% year-over-year raises concerns about its ability to sustain growth in a competitive market. Furthermore, the stock's current P/E ratio of 21.49 may indicate that it is relatively expensive compared to industry averages.
Want AI analysis of your entire portfolio?
Helm Terminal connects to your brokerage, analyzes every holding, and delivers actionable intelligence weekly. Free to start.
Get started freeHelm provides financial data for informational purposes only. This is not financial, investment, or tax advice. Consult a qualified professional before making financial decisions.
Watch my tickers
Get an email when something changes on your tickers: the exact quote, dated and sourced. No account, no brokerage connection, unsubscribe anytime.
Gilead Sciences, Inc. has a market capitalization of $182.90B and a current price of $145.74, reflecting a decrease of 0.62% from the previous close of $146.64. The company has a P/E ratio of 21.49 and a revenue growth of 2.40% year-over-year, while its EPS growth shows a significant increase of 1684.21%. The stock's 52-week high and low are $157.27 and $109, respectively.
Conversely, Gilead's revenue growth of only 2.40% year-over-year raises concerns about its ability to sustain growth in a competitive market. Furthermore, the stock's current P/E ratio of 21.49 may indicate that it is relatively expensive compared to industry averages.
Some investors highlight Gilead's impressive EPS growth of 1684.21% as a sign of potential profitability improvement. Additionally, the company’s strong return on equity (ROE) of 37.48% suggests effective management and capital utilization.
Some investors highlight Gilead's impressive EPS growth of 1684.21% as a sign of potential profitability improvement. Additionally, the company’s strong return on equity (ROE) of 37.48% suggests effective management and capital utilization. Conversely, Gilead's revenue growth of only 2.40% year-over-year raises concerns about its ability to sustain growth in a competitive market. Furthermore, the stock's current P/E ratio of 21.49 may indicate that it is relatively expensive compared to industry averages.
Gilead Sciences, Inc. has a market capitalization of $182.90B and a current price of $145.74, reflecting a decrease of 0.62% from the previous close of $146.64. The company has a P/E ratio of 21.49 and a revenue growth of 2.40% year-over-year, while its EPS growth shows a significant increase of 1684.21%. The stock's 52-week high and low are $157.27 and $109, respectively.
Helm's analysis is generated by an AI model from live market data. It identifies risk signals, opportunities, and key metrics based on current fundamentals, recent price action, and analyst consensus. It does not execute trades, issue certified investment advice, or predict future prices.
Not financial advice. Informational use only. AI-generated content may contain errors. Consult a licensed financial advisor before making investment decisions. Helm Terminal is not registered as an investment advisor.
Helm Terminal offers free AI-powered stock analysis for GILD at helmterminal.dev/analyze/GILD, updated continuously during US market hours. No signup required.